| The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. L Shi, G Campbell, WD Jones, F Campagne, Z Wen, SJ Walker, Z Su, ... Nature biotechnology 28 (8), 827, 2010 | 884 | 2010 |
| A heuristic approach to determine an appropriate number of topics in topic modeling W Zhao, JJ Chen, R Perkins, Z Liu, W Ge, Y Ding, W Zou BMC bioinformatics 16, 1-10, 2015 | 468 | 2015 |
| FDA-approved drug labeling for the study of drug-induced liver injury M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong Drug discovery today 16 (15-16), 697-703, 2011 | 429 | 2011 |
| In silico drug repositioning–what we need to know Z Liu, H Fang, K Reagan, X Xu, DL Mendrick, W Slikker Jr, W Tong Drug discovery today 18 (3-4), 110-115, 2013 | 207 | 2013 |
| Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology IW Deveson, B Gong, K Lai, JS LoCoco, TA Richmond, J Schageman, ... Nature biotechnology 39 (9), 1115-1128, 2021 | 185 | 2021 |
| A wavelength selection method based on randomization test for near-infrared spectral analysis H Xu, Z Liu, W Cai, X Shao Chemometrics and Intelligent Laboratory Systems 97 (2), 189-193, 2009 | 172 | 2009 |
| Mining FDA drug labels using an unsupervised learning technique-topic modeling H Bisgin, Z Liu, H Fang, X Xu, W Tong BMC bioinformatics 12 (10), 1-8, 2011 | 131 | 2011 |
| Comparing SVM and ANN based machine learning methods for species identification of food contaminating beetles H Bisgin, T Bera, H Ding, HG Semey, L Wu, Z Liu, AE Barnes, DA Langley, ... Scientific reports 8 (1), 6532, 2018 | 129 | 2018 |
| Toxicogenomics: A 2020 Vision Z Liu, R Huang, R Roberts, W Tong Trends in Pharmacological Sciences 40 (2), 92-103, 2019 | 118 | 2019 |
| AI-based language models powering drug discovery and development Z Liu, RA Roberts, M Lal-Nag, X Chen, R Huang, W Tong Drug Discovery Today 26 (11), 2593-2607, 2021 | 114 | 2021 |
| Lessons Learned from Two Decades of Anticancer Drugs Z Liu, B Delavan, R Roberts, W Tong Trends in Pharmacological Sciences 38 (10), 852-872, 2017 | 112 | 2017 |
| Toward Clinical Implementation of Next-Generation Sequencing-Based Genetic Testing in Rare Diseases: Where Are We? Z Liu, L Zhu, R Roberts, W Tong Trends in Genetics 35 (11), 852-867, 2019 | 108 | 2019 |
| t4 report: Supporting Read-Across Using Biological Data H Zhu, M Bouhifd, N Kleinstreuer, ED Kroese, Z Liu, T Luechtefeld, ... Altex 33 (2), 167, 2016 | 106 | 2016 |
| Drug-induced liver injury severity and toxicity (DILIst): Binary classification of 1279 drugs by human hepatotoxicity S Thakkar, T Li, Z Liu, L Wu, R Roberts, W Tong Drug discovery today 25 (1), 201-208, 2020 | 101 | 2020 |
| Translating clinical findings into knowledge in drug safety evaluation-drug induced liver injury prediction system (DILIps) Z Liu, Q Shi, D Ding, R Kelly, H Fang, W Tong PLoS computational biology 7 (12), e1002310, 2011 | 101 | 2011 |
| The liver toxicity knowledge base: a systems approach to a complex end point M Chen, J Zhang, Y Wang, Z Liu, R Kelly, G Zhou, H Fang, J Borlak, ... Clinical Pharmacology & Therapeutics 93 (5), 409-412, 2013 | 96 | 2013 |
| Computational drug repositioning for rare diseases in the era of precision medicine B Delavan, R Roberts, R Huang, W Bao, W Tong, Z Liu Drug discovery today 23 (2), 382-394, 2018 | 85 | 2018 |
| Similarities and differences between variants called with human reference genome HG19 or HG38 B Pan, R Kusko, W Xiao, Y Zheng, Z Liu, C Xiao, S Sakkiah, W Guo, ... BMC bioinformatics 20 (2), 17-29, 2019 | 84 | 2019 |
| Investigating drug repositioning opportunities in FDA drug labels through topic modeling H Bisgin, Z Liu, R Kelly, H Fang, X Xu, W Tong BMC bioinformatics 13, 1-9, 2012 | 81 | 2012 |
| Five-feature Model for Developing the Classifier for Synergistic vs Antagonistic Drug Combinations Built by XGBoost X Ji, W Tong, Z Liu, T Shi Frontiers in genetics 10, 600, 2019 | 63 | 2019 |
Weida TongNCTRVerified email at FDA.HHS.gov
